A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: Evolution of a regimen

European Journal of Cancer

Volumn 34, Issue 5, 1998, Pages 619-626

  De Gramont, A ^a   Louvet, G ^a   Andre T ^b   Tournigand, C ^b   Krulik, M ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL TENON   (France)

Author keywords

5 fluorouracil; Colorectal cancer; Continuous infusion; GERCOD; Leucovorin

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0032055888     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00364-X     Document Type: Article

References (41)

1. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
2. Budd GT, Fleming TR, Bukowski RM, et al. 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study. J Clin Oncol 1987, 5, 272-277.
3. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987, 5, 1559-1565.
4. Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989, 7, 1419-1426.
5. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 7, 1407-1418.
6. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994, 12, 14-20.
7. Doroshow JH, Multhauf P, Leong L, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990, 8, 491-501.
8. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991, 9, 1967-1972.
9. Grem JL, Hoth DF, Hamilton JM, King SA, Leyland-Jones B. Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep 1987,71, 1249-1264.
10. Machover D, Goldschmidt E, Chollet P, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986, 4, 685-696.
11. de Gramont A, Thirion P. Rationale for high-dose folinic acid and 5-fluorouracil in short continuous infusion in colo-rectal cancer. Cont Inf Newsl 1994, 2, 8-15.
12. Pinedo HM, Peters GF. Fluorouracil: biochemistry and phar-macology. J Clin Oncol 1988, 6, 1653-1664.
13. Rougier PH, Paillot B, Laplanche A, et al. End results of a multicentric randomized trial comparing 5 FU in continuous systemic infusion (CI) to bolus administration (B) in measurable metastatic colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1992, 11, 163.
14. Lokich JJ, Ahlgren JD, Gullo JJ, Phillips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989, 7, 425-432.
15. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 1995, 13, 1303-1311.
16. Hansen RM, Ryan L, Anderson T, et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996, 88, 668-674.
17. de Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988, 24, 1499-1503.
18. de Gramont A, Bosset J-F, Milan C, et al. A randomized trial comparing monthly low-dose leucovorin-5-fluorouracil bolus with bimonthly high-dose leucovorin-5-fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study (FFCD, GERCOD, SNFMI). J Clin Oncol 1997, 15, 808-815.
19. de Gramont A, Louvet C, Bennamoun M, et al. Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. J Infusional Chemother 1996, 6, 97-101.
20. Beerblock K, Rinaldi Y, André T, et al. Bimonthly high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in advanced colorectal cancer. Cancer 1997, 79, 1100-1105.
21. Tournigand C, Louvet C, de Gramont A, et al. Bimonthly highdose leucovorin and 5-fluorouracil 48-hour infusion with alfa-2a interferon in advanced colorectal cancer. Cancer 1997, 79, 1094-1099.
22. de Gramont A, Vignoud J, Tournigand C, Louvet C, Varette C. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997, 33, 214-219.
23. de Gramont A, Louvet C, Raymond E, et al. Bimonthly highdose leucovorin (LV), 5-fluorouracil (5FU) 48-h infusion with oxaliplatin in metastatic colorectal cancer (MCRC) resistant to the same LV-5FU regimen [Abstract]. Ann Oncol 1996, 7 (Suppl. 5), 38.
24. Sobrero AF, Aschele C, Guglielmi AP, et al. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 1993, 85, 1937-1944.
25. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996, 77, 441-451.
26. Ardalan B, Chua L, Tian EM, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991, 9, 625-630.
27. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993, 53, 5970-5976.
28. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato (tram-1-1,2-diaminocyclohexane) platinum (II): new experimental data. Biomed Pharmacother 1989,43, 251-260.
29. Kraker AJ, Moore CW. Accumulation of cis-diamminedichloroplatinum and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res 1988, 48, 9-13.
30. Moreau S, Machover D, de Gramont A, et al. Phase II trial of oxaliplatin: L-OHP® in patients with colorectal carcinoma (CRC) previously resistant to 5-fluorouracil (5FU) and folinic acid (FA) [Abstract]. Proc Am Soc Clin Oncol 1993, 12, 214.
31. Diaz-Rubio E, Marty M, Extra JM, et al. Multicentric phase II study with oxaliplatin (L-OHP) in 5-FU refractory patients with advanced colorectal cancer (ACC) [Abstract]. Proceedings of the Fifth International Congress on Anti-Cancer Chemotherapy. Paris, February 1995, 161.
32. Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992, 69, 893-900.
33. Levi F, Zidani R, Di Palma M, et al. Improved therapeutic index through ambulatory circadian rhythmic delivery (CRD) of high dose 3-drug chemotherapy in a randomized phase III multicenter trial [Abstract]. Proc Am Soc Clin Oncol 1994, 13, 197.
34. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7, 95-98.
35. de Gramont A, Louvet C, André T, et al. A simplified bimonthly regimen with leucovorin (LV) and 5-fluorouracil (5-FU) for metastatic colorectal cancer (MCRC). Feasibility study [Abstract]. Proc Am Soc Clin Oncol 1997, 16, 287a.
36. André T, Bensmaine MA, Louvet C, et al. Addition of oxaliplatin (Eloxatine®) to the same leucovorin (LV) and 5-fluorour-acil (5FU) bimonthly regimens after progression in patients (pts) with metastatic colorectal cancer (MCRC): preliminary report [Abstract]. Proc Am Soc Clin Oncol 1997, 16, 270a.
37. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: preliminary results of INT-0089 [Abstract]. Proc Am Soc Clin Oncol 1996, 15, 211.
38. Mamounas EP, Rockette H, Jones J, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs Dukes' C colon cancer: Results from fourNSABP adjuvant studies (C-01, C-
39. C-03, C-04) [Abstract]. ProcAm Soc Clin Oncol 1996,15, 205.
40. Scheithauer W, Marczell A, Depisch D, et al. Combined intravenous (IV) and intraperitoneal (IP) chemotherapy with 5-fluorouracil (5-FU) + leucovorin (LV) versus 5-FU + levamisole for adjuvant therapy of resected colon carcinoma [Abstract]. Proc Am Soc Clin Oncol 1996, 15, 216.
41. Tonelli F, Periti P, Mazzei T, et al. A randomized multicenter study comparing 5-fluorouracil (5-FU) and L-folinic acid (L-LV) alone or with levamisole (LEV) or interferon α2A (IFNα2A) as adjuvant therapy for colorectal cancer [Abstract]. Proc Am Soc Clin Oncol 1996, 15,226.